Cargando…
Revealing the Mechanism of Huazhi Rougan Granule in the Treatment of Nonalcoholic Fatty Liver Through Intestinal Flora Based on 16S rRNA, Metagenomic Sequencing and Network Pharmacology
Background: The incidence of Nonalcoholic Fatty Liver (NAFL) is increasing year by year, growing evidence suggests that the intestinal flora plays a causative role in NAFL. Huazhi Rougan Granule (HRG) is commonly used in the clinical treatment of NAFL. It is reported that it can reduce lipids and pr...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9086680/ https://www.ncbi.nlm.nih.gov/pubmed/35559233 http://dx.doi.org/10.3389/fphar.2022.875700 |
_version_ | 1784704058957758464 |
---|---|
author | Liu, Yingying Tan, Yingying Huang, Jiaqi Wu, Chao Fan, Xiaotian Stalin, Antony Lu, Shan Wang, Haojia Zhang, Jingyuan Zhang, Fanqin Wu, Zhishan Li, Bing Huang, Zhihong Chen, Meilin Cheng, Guoliang Mou, Yanfang Wu, Jiarui |
author_facet | Liu, Yingying Tan, Yingying Huang, Jiaqi Wu, Chao Fan, Xiaotian Stalin, Antony Lu, Shan Wang, Haojia Zhang, Jingyuan Zhang, Fanqin Wu, Zhishan Li, Bing Huang, Zhihong Chen, Meilin Cheng, Guoliang Mou, Yanfang Wu, Jiarui |
author_sort | Liu, Yingying |
collection | PubMed |
description | Background: The incidence of Nonalcoholic Fatty Liver (NAFL) is increasing year by year, growing evidence suggests that the intestinal flora plays a causative role in NAFL. Huazhi Rougan Granule (HRG) is commonly used in the clinical treatment of NAFL. It is reported that it can reduce lipids and protect the liver, but no research has confirmed whether the drug’s effect is related to the intestinal flora. Therefore, we investigated whether the effect of HRG is related to the regulation of intestinal flora to further explore the mechanism of HRG in the treatment of NAFL through intestinal flora. Methods: In this study, C57BL/6J mice were fed a high-fat diet for 10 weeks, and the high-fat diet plus HRG or polyene phosphatidylcholine capsules were each administered by gavage for 5 weeks. High-throughput sequencing, network pharmacology, and molecular docking were used to explore the mechanism of HRG in the treatment of NAFL through intestinal flora. Results: HRG treatment can reduce body weight gain, lipid accumulation in liver and lipogenesis and reduce serum biochemical indexes in high-fat-fed mice. Analysis of intestinal flora showed that HRG changed the composition of intestinal flora, which was characterized by a decrease in the Firmicutes/Bacteroidetes ratio. Moreover, the species distribution was significantly correlated with AKP, HDL-C, and TG. Metagenetic analysis showed that HRG altered the functional composition and functional diversity of microorganisms, which was mainly characterized by an increase in the abundance of metabolic pathways. The network pharmacology results show that the mechanism of HRG in the treatment of NAFL through intestinal flora is mainly reflected in the biological process of gene function and related to infectious diseases, immune systems, and signal transduction pathways, such as cytokine-cytokine receptor interaction, Chagas disease, IL-17 signaling pathway and other signaling pathways. Conclusion: These results strongly suggest that HRG may alleviate NAFL by preventing IFD. |
format | Online Article Text |
id | pubmed-9086680 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-90866802022-05-11 Revealing the Mechanism of Huazhi Rougan Granule in the Treatment of Nonalcoholic Fatty Liver Through Intestinal Flora Based on 16S rRNA, Metagenomic Sequencing and Network Pharmacology Liu, Yingying Tan, Yingying Huang, Jiaqi Wu, Chao Fan, Xiaotian Stalin, Antony Lu, Shan Wang, Haojia Zhang, Jingyuan Zhang, Fanqin Wu, Zhishan Li, Bing Huang, Zhihong Chen, Meilin Cheng, Guoliang Mou, Yanfang Wu, Jiarui Front Pharmacol Pharmacology Background: The incidence of Nonalcoholic Fatty Liver (NAFL) is increasing year by year, growing evidence suggests that the intestinal flora plays a causative role in NAFL. Huazhi Rougan Granule (HRG) is commonly used in the clinical treatment of NAFL. It is reported that it can reduce lipids and protect the liver, but no research has confirmed whether the drug’s effect is related to the intestinal flora. Therefore, we investigated whether the effect of HRG is related to the regulation of intestinal flora to further explore the mechanism of HRG in the treatment of NAFL through intestinal flora. Methods: In this study, C57BL/6J mice were fed a high-fat diet for 10 weeks, and the high-fat diet plus HRG or polyene phosphatidylcholine capsules were each administered by gavage for 5 weeks. High-throughput sequencing, network pharmacology, and molecular docking were used to explore the mechanism of HRG in the treatment of NAFL through intestinal flora. Results: HRG treatment can reduce body weight gain, lipid accumulation in liver and lipogenesis and reduce serum biochemical indexes in high-fat-fed mice. Analysis of intestinal flora showed that HRG changed the composition of intestinal flora, which was characterized by a decrease in the Firmicutes/Bacteroidetes ratio. Moreover, the species distribution was significantly correlated with AKP, HDL-C, and TG. Metagenetic analysis showed that HRG altered the functional composition and functional diversity of microorganisms, which was mainly characterized by an increase in the abundance of metabolic pathways. The network pharmacology results show that the mechanism of HRG in the treatment of NAFL through intestinal flora is mainly reflected in the biological process of gene function and related to infectious diseases, immune systems, and signal transduction pathways, such as cytokine-cytokine receptor interaction, Chagas disease, IL-17 signaling pathway and other signaling pathways. Conclusion: These results strongly suggest that HRG may alleviate NAFL by preventing IFD. Frontiers Media S.A. 2022-04-26 /pmc/articles/PMC9086680/ /pubmed/35559233 http://dx.doi.org/10.3389/fphar.2022.875700 Text en Copyright © 2022 Liu, Tan, Huang, Wu, Fan, Stalin, Lu, Wang, Zhang, Zhang, Wu, Li, Huang, Chen, Cheng, Mou and Wu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Liu, Yingying Tan, Yingying Huang, Jiaqi Wu, Chao Fan, Xiaotian Stalin, Antony Lu, Shan Wang, Haojia Zhang, Jingyuan Zhang, Fanqin Wu, Zhishan Li, Bing Huang, Zhihong Chen, Meilin Cheng, Guoliang Mou, Yanfang Wu, Jiarui Revealing the Mechanism of Huazhi Rougan Granule in the Treatment of Nonalcoholic Fatty Liver Through Intestinal Flora Based on 16S rRNA, Metagenomic Sequencing and Network Pharmacology |
title | Revealing the Mechanism of Huazhi Rougan Granule in the Treatment of Nonalcoholic Fatty Liver Through Intestinal Flora Based on 16S rRNA, Metagenomic Sequencing and Network Pharmacology |
title_full | Revealing the Mechanism of Huazhi Rougan Granule in the Treatment of Nonalcoholic Fatty Liver Through Intestinal Flora Based on 16S rRNA, Metagenomic Sequencing and Network Pharmacology |
title_fullStr | Revealing the Mechanism of Huazhi Rougan Granule in the Treatment of Nonalcoholic Fatty Liver Through Intestinal Flora Based on 16S rRNA, Metagenomic Sequencing and Network Pharmacology |
title_full_unstemmed | Revealing the Mechanism of Huazhi Rougan Granule in the Treatment of Nonalcoholic Fatty Liver Through Intestinal Flora Based on 16S rRNA, Metagenomic Sequencing and Network Pharmacology |
title_short | Revealing the Mechanism of Huazhi Rougan Granule in the Treatment of Nonalcoholic Fatty Liver Through Intestinal Flora Based on 16S rRNA, Metagenomic Sequencing and Network Pharmacology |
title_sort | revealing the mechanism of huazhi rougan granule in the treatment of nonalcoholic fatty liver through intestinal flora based on 16s rrna, metagenomic sequencing and network pharmacology |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9086680/ https://www.ncbi.nlm.nih.gov/pubmed/35559233 http://dx.doi.org/10.3389/fphar.2022.875700 |
work_keys_str_mv | AT liuyingying revealingthemechanismofhuazhirougangranuleinthetreatmentofnonalcoholicfattyliverthroughintestinalflorabasedon16srrnametagenomicsequencingandnetworkpharmacology AT tanyingying revealingthemechanismofhuazhirougangranuleinthetreatmentofnonalcoholicfattyliverthroughintestinalflorabasedon16srrnametagenomicsequencingandnetworkpharmacology AT huangjiaqi revealingthemechanismofhuazhirougangranuleinthetreatmentofnonalcoholicfattyliverthroughintestinalflorabasedon16srrnametagenomicsequencingandnetworkpharmacology AT wuchao revealingthemechanismofhuazhirougangranuleinthetreatmentofnonalcoholicfattyliverthroughintestinalflorabasedon16srrnametagenomicsequencingandnetworkpharmacology AT fanxiaotian revealingthemechanismofhuazhirougangranuleinthetreatmentofnonalcoholicfattyliverthroughintestinalflorabasedon16srrnametagenomicsequencingandnetworkpharmacology AT stalinantony revealingthemechanismofhuazhirougangranuleinthetreatmentofnonalcoholicfattyliverthroughintestinalflorabasedon16srrnametagenomicsequencingandnetworkpharmacology AT lushan revealingthemechanismofhuazhirougangranuleinthetreatmentofnonalcoholicfattyliverthroughintestinalflorabasedon16srrnametagenomicsequencingandnetworkpharmacology AT wanghaojia revealingthemechanismofhuazhirougangranuleinthetreatmentofnonalcoholicfattyliverthroughintestinalflorabasedon16srrnametagenomicsequencingandnetworkpharmacology AT zhangjingyuan revealingthemechanismofhuazhirougangranuleinthetreatmentofnonalcoholicfattyliverthroughintestinalflorabasedon16srrnametagenomicsequencingandnetworkpharmacology AT zhangfanqin revealingthemechanismofhuazhirougangranuleinthetreatmentofnonalcoholicfattyliverthroughintestinalflorabasedon16srrnametagenomicsequencingandnetworkpharmacology AT wuzhishan revealingthemechanismofhuazhirougangranuleinthetreatmentofnonalcoholicfattyliverthroughintestinalflorabasedon16srrnametagenomicsequencingandnetworkpharmacology AT libing revealingthemechanismofhuazhirougangranuleinthetreatmentofnonalcoholicfattyliverthroughintestinalflorabasedon16srrnametagenomicsequencingandnetworkpharmacology AT huangzhihong revealingthemechanismofhuazhirougangranuleinthetreatmentofnonalcoholicfattyliverthroughintestinalflorabasedon16srrnametagenomicsequencingandnetworkpharmacology AT chenmeilin revealingthemechanismofhuazhirougangranuleinthetreatmentofnonalcoholicfattyliverthroughintestinalflorabasedon16srrnametagenomicsequencingandnetworkpharmacology AT chengguoliang revealingthemechanismofhuazhirougangranuleinthetreatmentofnonalcoholicfattyliverthroughintestinalflorabasedon16srrnametagenomicsequencingandnetworkpharmacology AT mouyanfang revealingthemechanismofhuazhirougangranuleinthetreatmentofnonalcoholicfattyliverthroughintestinalflorabasedon16srrnametagenomicsequencingandnetworkpharmacology AT wujiarui revealingthemechanismofhuazhirougangranuleinthetreatmentofnonalcoholicfattyliverthroughintestinalflorabasedon16srrnametagenomicsequencingandnetworkpharmacology |